Navigation Links
Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
Date:12/13/2012

1,354

945Cost of TOS

475

620

1,174

1,104Research and development

436

1,008

823

1,616Sales and marketing

680

651

1,389

1,262General and administrative

1,201

1,470

2,340

3,130  Loss from Operations($1,916)($2,469)($3,516)($4,685)Other (Loss) Income

(57)

120

223

298  Net Loss before income tax expense($1,973)($2,349)($3,293)($4,387)Income taxes

1

-

4

-  Net Loss($1,974)($2,349)($3,297)($4,387)  Earnings per share- basic and diluted($0.04)($0.05)($0.07)($0.09)Weighted average shares outstanding- basic and diluted

47,079,000

46,790,000

47,073,000

46,606,000 Condensed Consolidated Balance Sheets Balance as of  October 31, 2012(unaudited)April 30, 2012 Cash and cash equivalents

$2,161

$4,716Accounts receivable

627

584Other current assets

95

205  Total current assets2,8835,505Restricted cash

188

188Property and equipment, net

485

560Goodwill

669

669  Total assets$4,225$6,922Accounts payable and accrued liabilities

$1,723

$2,301Deferred revenue

1,205

1,185  Total current liabilities2,9283,486Warrant liability

322

555Redeemable common stock

8,159

8,159Stockholders' deficit

(7,184)

(5,278)  Total liabilities, redeemable common stock andstockholders' deficit$4,225$6,922 Condensed Consolidated Statements of Cash Flows (Unaudited)Six Months Ended October 31,20122011Cash flows from operating activities:Net Loss

($3,297)

($4,387)Adjustments to reconcile net cash used in operations:  Stock-based compensation expense

1,364

1,868
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
8. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. International Oncology Innovators Meeting in Hamburg
11. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... The report provides basic information ... application and industry overview. This report also presents ... Production is separated by regions, technology and applications. ... downstream client survey, marketing channels, industry development trend ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... A modeling study from the European Alps suggests that ... will probably underestimate the long-term effects of recent climate ... around Stefan Dullinger from the Department of Conservation Biology, ... presents a new modeling tool to predict migration of ...
... Sauropod dinosaurs could in principle have produced enough of the ... years ago, at a time when the Earth was warm ... 8th issue of Current Biology, a Cell Press ... and unusually long necks, were widespread about 150 million years ...
... are being investigated as a way of improving drug response ... launched today (Monday). Scientists at the Cancer Research UK ... (ECMC) in Leicester will investigate whether tablets containing curcumin ... to the standard treatment for bowel cancer that has spread. ...
Cached Biology News:European mountain plant population shows delayed response to climate change 2Gaseous emissions from dinosaurs may have warmed prehistoric earth 2Trial launched into curry chemical's cancer-fighting properties 2